User menu

Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy – case report and literature review

Bibliographic reference Constantinescu, Stefan Matei ; BUYSSCHAERT, Benoit ; Haufroid, Vincent ; Broly, Franck ; Jadoul, Michel ; et. al. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy – case report and literature review. In: BMC Nephrology, Vol. 18, no.1 (2017)
Permanent URL
  1. World Health Organization. Global Tuberculosis Report 20th Edition; 2015.
  2. Adams Peter, White Chester, ISONIAZID-INDUCED ENCEPHALOPATHY, 10.1016/s0140-6736(65)91833-7
  3. Miscoria G, Leneveu A, Walle C, et al. Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation. Ann Biol Clin (Paris). 1988;46:734–40.
  4. Liyanage Thaminda, Ninomiya Toshiharu, Jha Vivekanand, Neal Bruce, Patrice Halle Marie, Okpechi Ikechi, Zhao Ming-hui, Lv Jicheng, Garg Amit X, Knight John, Rodgers Anthony, Gallagher Martin, Kotwal Sradha, Cass Alan, Perkovic Vlado, Worldwide access to treatment for end-stage kidney disease: a systematic review, 10.1016/s0140-6736(14)61601-9
  5. Korzets A., Gafter U., Tuberculosis prophylaxis for the chronically dialysed patient--yes or no?, 10.1093/ndt/14.12.2857
  6. Horne D. J., Narita M., Spitters C. L., Parimi S., Dodson S., Limaye A. P., Challenging Issues in Tuberculosis in Solid Organ Transplantation, 10.1093/cid/cit488
  7. Siskind Mark S., Thienemann Dana, Kirlin Linda, Isoniazid-Induced Neurotoxicity in Chronic Dialysis Patients: Report of Three Cases and a Review of the Literature, 10.1159/000187331
  8. CDC 24/7: Saving Lives, Protecting People. Atlanta: Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Updated 2013 April 3 Available from: .
  9. Kasama Richard, Koch Terry, Canals-Navas Carmen, Pitone Joseph M., Vitamin b6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of the literature, 10.1016/s0272-6386(96)90103-1
  10. Mashimo Masami, Suzuki Tomokazu, Abe Masako, Deguchi Takeo, Molecular genotyping of N-acetylation polymorphism to predict phenotype, 10.1007/bf00210758
  11. Kinzig-Schippers M., Tomalik-Scharte D., Jetter A., Scheidel B., Jakob V., Rodamer M., Cascorbi I., Doroshyenko O., Sorgel F., Fuhr U., Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?, 10.1128/aac.49.5.1733-1738.2005
  12. Azuma Junichi, , Ohno Masako, Kubota Ryuji, Yokota Soichiro, Nagai Takayuki, Tsuyuguchi Kazunari, Okuda Yasuhisa, Takashima Tetsuya, Kamimura Sayaka, Fujio Yasushi, Kawase Ichiro, NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy, 10.1007/s00228-012-1429-9
  13. Podgorná Eliška, Diallo Issa, Vangenot Christelle, Sanchez-Mazas Alicia, Sabbagh Audrey, Černý Viktor, Poloni Estella S., Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa, 10.1186/s12862-015-0543-6